Beyond the Diagnosis: Humanizing the First Oncology Visit
Beyond the Diagnosis: Humanizing the First Oncology Visit

At the ASCO Annual Meeting, an expert panel convened to discuss the the nuances of and challenges related to GU oncology patient-centered care in an increasingly complex healthcare system. Moderated by Dr. Christopher Wallis, the roundtable consisted of a diverse range of perspectives, including Drs. Vadim Koshkin, Jacqueline Brown, Brenda Martone, and Alicia Morgans.

In the first segment, the panel explores the emotional weight of a cancer diagnosis. They discuss the importance of empathetic communication, level-setting, and a multidisciplinary approach to help patients process their diagnosis and build trust early in the care journey.

Advertisement

Latest News

NEOAVAX Trial: Neoadjuvant Avelumab and Axitinib for Localized High-Risk RCC
NEOAVAX Trial: Neoadjuvant Avelumab and Axitinib for Localized High-Risk RCC
Axel Bex, MD, PhDLocalized Renal Cell Carcinoma | July 1, 2025
Professor Bex discusses the phase II NEOAVAX trial that evaluated avelumab/axitinib as neoadjuvant therapy in localized RCC.
Intravesical Gemcitabine/Docetaxel as First-Line Therapy for Patients With NMIBC
Intravesical Gemcitabine/Docetaxel as First-Line Therapy for Patients With NMIBC
Jessica GangaNon-Muscle Invasive Urothelial Carcinoma | July 1, 2025
Researchers find promise in Gem/Doce as an alternative therapy for patients with NMIBC recurrence after BCG induction.
Targeting CD70 With ALLO-316 in Advanced Clear Cell RCC: Updated Phase 1 Results From TRAVERSE
Targeting CD70 With ALLO-316 in Advanced Clear Cell RCC: Updated Phase 1 Results From TRAVERSE
Samer Srour, MBAdvanced Renal Cell Carcinoma | June 30, 2025
Samer Srour, MB, talks about the updated ALLO-316 and its use in targeting CD70 in patients with advanced ccRCC.
CHAI vs Clinical Judgment: A New Frontier in NMIBC Personalization
CHAI vs Clinical Judgment: A New Frontier in NMIBC Personalization
Vignesh T. Packiam, MDNon-Muscle Invasive Urothelial Carcinoma | June 30, 2025
Drs. Packiam and Yerram conclude with an AI-powered pathology tool designed to predict response to BCG in NMIBC.
SunRISe-1 Cohort 4 and Papillary NMIBC Treatment
SunRISe-1 Cohort 4 and Papillary NMIBC Treatment
Vignesh T. Packiam, MDNon-Muscle Invasive Urothelial Carcinoma | June 30, 2025
Drs. Packiam and Yerram shift focus to SunRISe-1 Cohort 4, which examined BCG-unresponsive papillary disease.
Checkpoint Inhibitors Meet BCG: Interpreting the CREST Trial for NMIBC
Checkpoint Inhibitors Meet BCG: Interpreting the CREST Trial for NMIBC
Vignesh T. Packiam, MDNon-Muscle Invasive Urothelial Carcinoma | June 30, 2025
Drs. Packiam and Yerram contextualize recent data from the CREST trial, which evaluated sasanlimab with BCG for HR NMIBC.
The Innovation Dilemma: More NMIBC Therapies, But No Comparative Trials
The Innovation Dilemma: More NMIBC Therapies, But No Comparative Trials
Vignesh T. Packiam, MDNon-Muscle Invasive Urothelial Carcinoma | June 30, 2025
Drs. Packiam and Yerram focus on how agents like gem/doce, pembro, nadofaragene, cretostimogene, and TAR-200 are used.
Tailoring Treatment in NMIBC: From Tumor Biology to TAR-200
Tailoring Treatment in NMIBC: From Tumor Biology to TAR-200
Vignesh T. Packiam, MDNon-Muscle Invasive Urothelial Carcinoma | June 30, 2025
Drs. Packiam and Yerram discuss TAR-200 and the ongoing SunRISe-3 trial exploring its effectiveness amid BCG shortages.
Rethinking NMIBC: Evolving Beyond BCG
Rethinking NMIBC: Evolving Beyond BCG
Vignesh T. Packiam, MDNon-Muscle Invasive Urothelial Carcinoma | June 30, 2025
Drs. Packiam and Yerram discuss the emergence of gem/doce as a promising alternative to BCG.
Radiopharmaceutical Trials in Prostate Cancer: Evolving Treatments and Combination Therapies
Radiopharmaceutical Trials in Prostate Cancer: Evolving Treatments and Combination Therapies
Robert Flavell, MD, PhDRLT | June 27, 2025
Dr. Flavell discusses how landmark studies have shaped current trial designs, and growing interest in combination therapies.
Ongoing Radiopharmaceutical Therapy Trials in Prostate Cancer
Ongoing Radiopharmaceutical Therapy Trials in Prostate Cancer
Robert Flavell, MD, PhDRLT | June 27, 2025
Dr. Flavell highlights the expansion of lutetium PSMA therapies into earlier disease settings: HSPC and oligometastatic PC.
Navigating the Potential of Liquid Biopsy in Kidney Cancer Care
Navigating the Potential of Liquid Biopsy in Kidney Cancer Care
Chinmay Jani, MDRenal Cell Carcinoma Diagnostics | June 26, 2025
Drs. Joyce and Jani look toward the future of liquid biopsy in RCC care and how new technology, like AI, will play a role.
Advertisement
Advertisement
Editorial Advisory Board
Brian Rini, MD, FASCO
Brian Rini, MD, FASCOEditor | Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center
Thomas Powles, MBBS, MRCP, MD
Thomas Powles, MBBS, MRCP, MDEditor | Director, Barts Cancer Centre at St. Bartholomew's Hospital
Katy Beckermann, MD, PhD
Katy Beckermann, MD, PhDEditor | Medical Director of GU Clinical Research at Tennessee Oncology
Christopher Wallis, MD, PhD, FRCSC
Christopher Wallis, MD, PhD, FRCSCAssistant Professor of Urology | University of Toronto
Akhil Abraham Saji, MD
Akhil Abraham Saji, MDEditor | Urologist at Swedish Health Services
David Ambinder, MD
David Ambinder, MDEditor | Urology Resident at New York Medical College/Westchester Medical Center

The Uromigos Live and Unplugged 2024

The Uromigos Live & Unplugged 2024
The Uromigos Live & Unplugged 2024

The Uromigos Live & Unplugged 2024 took place September 27-29 in Nashville, Tennessee.

This meeting was the third annual in-person event hosted by Thomas Powles, MD, and Brian Rini, MD, FASCO, in partnership with Mashup Media, featuring expert panels and audience discussion around the latest data in genitourinary oncology and vision for the future.

Expert Interviews

Teaching TURBT Over 5G: Integrating XR Headsets Into Urologic Practice
Teaching TURBT Over 5G: Integrating XR Headsets Into Urologic Practice
Evan Kovac, MDProstate Cancer | May 19, 2025
Dr. Evan Kovac speaks about his pioneering work with extended reality display technology in urologic surgery and education.
Bladder Cancer Without Cystectomy: Dr. Alexandre Zlotta on the Maturation of Trimodality Therapy
Bladder Cancer Without Cystectomy: Dr. Alexandre Zlotta on the Maturation of Trimodality Therapy
Alexandre Zlotta, MDMuscle Invasive Urothelial Carcinoma | May 15, 2025
Dr. Zlotta discusses the current state and future of bladder-sparing therapy in MIBC, including how to best select patients.
From VEGF to HIF-2 Targeting Drugs: Dr. James Brugarolas’ Journey to Transforming Kidney Cancer Treatment
From VEGF to HIF-2 Targeting Drugs: Dr. James Brugarolas’ Journey to Transforming Kidney Cancer Treatment
James “Jim” Brugarolas, MD, PhDRenal Cell Carcinoma | April 22, 2025
Dr. Brugarolas reflects on his lab's role in developing HIF-2 inhibitors and his ongoing work to improve patient outcomes.
Bladder-Sparing Innovations in MIBC: Dr. Elizabeth Plimack on the RETAIN Approach and Its Future
Bladder-Sparing Innovations in MIBC: Dr. Elizabeth Plimack on the RETAIN Approach and Its Future
Elizabeth Plimack, MD, MS, FASCOMuscle Invasive Urothelial Carcinoma | June 25, 2025
Dr. Plimack details RETAIN, from early findings with neoadjuvant ddMVAC to the evolution of RETAIN-1 and RETAIN-2.
Precision in Prostate Cancer: Dr. Amir Lebastchi on Tailoring Focal Therapy for Optimal Outcomes
Precision in Prostate Cancer: Dr. Amir Lebastchi on Tailoring Focal Therapy for Optimal Outcomes
Akhil Abraham Saji, MDLocalized | June 25, 2025
Drs. Saji and Lebastchi explore focal therapy, covering its historical evolution, techniques, and energy modalities.
Ahmed E. Ghazi – Revolutionizing and Scaling Surgical Training Through Simulation Models
Ahmed E. Ghazi – Revolutionizing and Scaling Surgical Training Through Simulation Models
David Ambinder, MDLocalized | June 25, 2025
Dr. Ghazi is recognized as a pioneer in patient-specific surgical simulation, using state-of-the-art techniques in surgery.

Knowledge Hubs

Curated clinical content based on conditions, therapies, and technologies

Prostate Cancer
Prostate Cancer
CRPC
CRPC
Localized
Localized
Prostate Cancer Diagnostics
Prostate Cancer Diagnostics
RLT
RLT
mHSPC/mCSPC
mHSPC/mCSPC
Renal Cell Carcinoma
Renal Cell Carcinoma
Localized Renal Cell Carcinoma
Localized Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
nccRCC
nccRCC
Renal Cell Carcinoma Diagnostics
Renal Cell Carcinoma Diagnostics
Testicular, Penile, and Rare Malignancies
Testicular, Penile, and Rare Malignancies
Urothelial Carcinoma
Urothelial Carcinoma
Advanced Urothelial Carcinoma
Advanced Urothelial Carcinoma
Muscle Invasive Urothelial Carcinoma
Muscle Invasive Urothelial Carcinoma
Non-Muscle Invasive Urothelial Carcinoma
Non-Muscle Invasive Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Urothelial Carcinoma Diagnostics
Urothelial Carcinoma Diagnostics
Prostate Cancer
Prostate Cancer
CRPC
CRPC
Localized
Localized
Prostate Cancer Diagnostics
Prostate Cancer Diagnostics

The Uromigos

Podcasts hosted by Professors Thomas Powles, MD, and Brian Rini, MD

Episode 428: ASCO 2025 Recap
Episode 428: ASCO 2025 Recap
Dr. Silke Gillessen joins the show to discuss highlights from the ASCO 2025 Annual Meeting with Brian and Tom.
# Posted on June 16, 2025
Episode 427: Emerging Data in Non-Muscle Invasive Bladder Cancer
Episode 427: Emerging Data in Non-Muscle Invasive Bladder Cancer
Dr. Joshua Meeks joins the podcast to give a stellar overview of emerging data in the NMIBC space.
# Posted on June 16, 2025
# Uromigos-Bladder Cancer
Episode 426: ASCO 2025 - AMPLITUDE Phase 3 of PARPi in mHSPC
Episode 426: ASCO 2025 - AMPLITUDE Phase 3 of PARPi in mHSPC
Dr. Gerhardt Attard discusses practice-changing data from AMPLITUDE, and the history of PARP inhibitor use.
# Posted on June 9, 2025
# Uromigos-ASCO

Conference Coverage

Live meeting highlights

NEOAVAX Trial: Neoadjuvant Avelumab and Axitinib for Localized High-Risk RCC
Axel Bex, MD, PhDLocalized Renal Cell Carcinoma | July 1, 2025
Professor Bex discusses the phase II NEOAVAX trial that evaluated avelumab/axitinib as neoadjuvant therapy in localized RCC.
View More
Targeting CD70 With ALLO-316 in Advanced Clear Cell RCC: Updated Phase 1 Results From TRAVERSE
Samer Srour, MBAdvanced Renal Cell Carcinoma | June 30, 2025
Samer Srour, MB, talks about the updated ALLO-316 and its use in targeting CD70 in patients with advanced ccRCC.
View More
Radiopharmaceutical Trials in Prostate Cancer: Evolving Treatments and Combination Therapies
Robert Flavell, MD, PhDRLT | June 27, 2025
Dr. Flavell discusses how landmark studies have shaped current trial designs, and growing interest in combination therapies.
View More
Ongoing Radiopharmaceutical Therapy Trials in Prostate Cancer
Robert Flavell, MD, PhDRLT | June 27, 2025
Dr. Flavell highlights the expansion of lutetium PSMA therapies into earlier disease settings: HSPC and oligometastatic PC.
View More

Video Insights

Clinical discussions with experts in the field

Network Websites

Blood Cancers Today provides hematologists and oncologists with news, education, and research relevant to their patients and practices. Featuring the latest clinical updates from all facets of the specialty, it offers thought-provoking insights and exclusive interviews from experts in the field.

MashupMD is an innovative medical news and social media aggregator. The platform is optimized to deliver rapid access to the latest headlines in health care and collections of key medical content based on what health care professionals around the world are reading and sharing.

Cancer Nursing Today delivers critical news, research, and commentary to support oncology nurses throughout their education and careers. Its goal is to advance oncology treatments and care practices and promote the nurse’s role in enhanced patient outcomes and quality of life.

DocWire News is a leading source of medical industry news for health care professionals, featuring breaking news, expert commentary, research analysis, and conference highlights. It covers a comprehensive range of clinical specialties, including cardiology, oncology, neurology, and more.

Urban Health Today is the leading independent news source that provides urban health care professionals with relevant research and policy developments that impact patients and their practices. Its coverage focuses on clinical, social, and environmental health disparities.

Powered by DocWire News

GI Oncology Now is the leading medical news resource for practicing oncologists and health care providers treating gastrointestinal malignancies, offering the latest study data and research breakthroughs related to colorectal, gastric, liver, pancreatic, and esophageal cancers.

Heme Today produces the latest news and research for hematologists and oncologists focused on blood disorders such as clotting, red and white blood cell, and iron disorders, including conference highlights, late-breaking research, interviews with leaders in the field, and more.

A medical news property for practicing oncologists treating lung malignancies, Lung Cancers Today features breaking news, commentary, expert interviews, and data analysis to inform providers on the latest research and most effective clinical practices in the lung cancers space.

Nephrology Times delivers the latest news in nephrological treatments and technologies, curating content from clinical trials, conference highlights, and perspectives from key opinion leaders, with the goal of better informing care decisions and improving patient outcomes.

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    About Us

    Contributors and Partners

    Editorial Policy

    Advertising

    Connect

    eNewsletters

    Calendar

    Contact Us

    Contribute

    Our Network

    MashupMD

    Cancer Nursing Today

    Urban Health Today

    Blood Cancers Today

    DocWire News

    © 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |